Investors should vote their shares by the deadlines to ensure the transaction proceeds. The stock is likely to trade close to the $38.00 offer price until closing. Monitor for any competing bids or regulatory issues that could delay or derail the deal.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Apr 20 $39.51entry
- T+1 · 7mo ago −0.05%α +0.60% · $39.49
- T+5 · 7mo ago 0.00%α −0.91% · $39.51
- T+20 · 6mo ago +0.33%α −3.87% · $39.64
- T+60 · due 4mo ago Pending
Price Chart
REPLAYWatch the reaction play outExecutive Summary
Centessa Pharmaceuticals (CNTA) is being acquired by Eli Lilly (LILY) in a $7.8B deal structured as a Scheme of Arrangement. Shareholders will receive $38.00 in cash per share plus a contingent value right (CVR) worth up to $9.00 per share based on future milestones. The deal, recommended by Centessa's board, is expected to close in Q3 2026 pending shareholder and regulatory approval.
Key Financial Metrics
Key Facts
- Eli Lilly is acquiring Centessa Pharmaceuticals for $38.00 per share in cash, plus a contingent value right (CVR) worth up to $9.00 per share.
- The total deal value is approximately $7.8 billion, including the CVR component.
- Centessa's board unanimously recommends shareholders vote in favor of the transaction.
- The deal structure is a Scheme of Arrangement under UK law, requiring approval from both shareholders and the UK High Court.
- The transaction is expected to close in the third quarter of 2026, subject to regulatory and antitrust approvals.
- Centessa's financial advisors, Centerview and Jefferies, provided fairness opinions supporting the transaction price.
Financial Impact
Total transaction value of $7.8 billion, with $38.00 in cash per share and a potential $9.00 per share from CVRs.
Risk Factors
- The transaction is subject to regulatory approval, which could be delayed or denied.
- The CVR component is contingent on future milestones and may not be fully realized.
- The deal could be derailed by a competing offer or a change in board recommendation.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| PREM14A Filing (Primary) | 0001193125-26-161682 |
| Document: d148719dexfilingfees.htm | 0001193125-26-161682 |
| Document: 0001193125-26-161682-index-headers.html | 0001193125-26-161682 |
| Document: 0001193125-26-161682-index.html | 0001193125-26-161682 |
| Document: 0001193125-26-161682.txt | 0001193125-26-161682 |
Track record
5 reports on CNTA
2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +8.31% at T+5 after the Mar 13, 2026 report. 3 of 3 went positive at some point.
Filters
- Jul 6, 202619w ago 15-12G Bearish 7/10 No price data
- Apr 17, 202630w ago PREM14A Bullish 9/10 Viewing Entry $39.51 to $39.51 · 0.00% −0.91% vs SPY
- Apr 13, 202631w ago DEFA14A Bullish 8/10 Entry $39.59 to $39.49 ▼ −0.25% −1.65% vs SPY
- Mar 13, 202635w ago Insider Cluster Bearish 7/10 Entry $28.29 to $25.94 ▲ +8.31% +6.27% vs SPY
- Mar 13, 202635w ago Insider Cluster Bearish 6/10 Entry $28.29 to $25.94 ▲ +8.31% +6.27% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers